Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains

Archives of General Psychiatry

Volumn 52, Issue 10, 1995, Pages 829-836

  Tsai, Guochuan ^a   Passani, Lucius A ^a   Slusher, Barbara S ^a,c   Carter, Ruth ^a   Baer, Lee ^a   Kleinman, Joel E ^b   Coyle, Joseph T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; GLUTAMIC ACID; NEUROLEPTIC AGENT;

ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN TISSUE; NEUROTRANSMISSION; SCHIZOPHRENIA;

ADULT; AGED; BRAIN; DIPEPTIDASES; DIPEPTIDES; FEMALE; GLUTAMATES; HIPPOCAMPUS; HUMAN; MALE; MIDDLE AGE; PREFRONTAL CORTEX; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028875197     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1995.03950220039008     Document Type: Article

References (46)

1. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett. 1980;20: 379–382.
2. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM. A ‘glutamatergic hypothesis’ of schizophrenia. J Clin Psychopharmacol. 1989;12: 1–13.
3. Javitts DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148: 1301–1308.
4. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Brenner JP, Henninger GR, Bowers MB, Charney DS. Subanaesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans: psychotominetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51: 199–214.
5. Sherman AD, Davidson AT, Baruah S, Hegwood TS, Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neurosci Lett. 1991;121: 77–80.
6. Deakin JFW, Slater P, Simpson MDC, Gilchrist AC, Skan WJ, Royston MC, Reynolds GP, Cross AJ. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem. 1989;52: 1781–1786.
7. Nishikawa T, Takashima M, Toru M. Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett. 1983;40: 245–250.
8. Kerwin RW, Patel S, Meldrum BS, Czudek C, Reynolds GP. Asymmetrical loss of glutamate receptors subtype in left hippocampus in schizophrenia. Lancet. 1988;1: 583–584.
9. Kerwin R, Patel S, Meldrum B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience. 1990;39: 25–32.
10. Simpson MDC, Slater P, Royston MC, Deakin JFW. Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia. Psychiatry Res. 1992;42: 273–282.
11. Kornhuber J, Mack-Burkhardt F, Riederer P, Hebenstreit GF, Reynolds GP, Andrews HB, Beckmann H. [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm Park Dis Dement Sect. 1989;77: 231–236.
12. Robinson MB, Coyle JT. Glutamate and related acidic excitatory neurotransmitters: from basic science to clinical application. FASEB J. 1987;1: 446–455.
13. Quirion R, Bayorh MS, Zerbe RL, Pert CV. Evidence for an endogenous peptide ligand for the phencyclidine receptor. Peptides. 1984;5: 967–973.
14. Zukin SR, Zukin RS, Vale W. An endogenous ligand of the brain s/PCP receptor antagonizes NMDA-induced neurotransmitter release. Brain Res. 1987;415: 84–89.
15. Tsai G, Stauch B, Sim L, Coyle JT. Immunocytochemical distribution of N-acetylaspartylglutamate in the rat forebrain and glutamatergic pathways. J Chem Neuroanat. 1993;6: 277–292.
16. Puttfarcken PS, Handen JS, Montgomery DT, Coyle JT, Werling LL. N-acetylaspartylglutamate modulation of N-methyl-D-aspartate stimulated [3H]norepinephrine release from rat hippocampal slices. J Pharmacol Exp Ther. 1993;266: 796–803.
17. Tsai G, Stauch B, Vernov J, Deshpondae J, Coyle JT. Selective in vivo release of N-acetylaspartylglutamate from rat optic pathway. Brain Res. 1990;518: 313–316.
18. Slusher BS, Robinson MB, Tsai G, Simmons ML, Richards SS, Coyle JT. Rat brain N-acetyl-alpha—linked acidic dipeptidase activity: purification and immunological characterization. J Biol Chem. 1990;265: 21297–21301.
19. Bogerts B, Ashtari M, Degreef G, Alvir JMJ, Bilder RM, Lieberman JA. Reduced temporal limbic structures volumes on magnetic resonance images in first episode schizophrenia. Psychiatry Res. 1990;35: 1–13.
20. Weinberger D, Berman KF, Suddath R, Torrey EF. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: an MRI and rCBF study of discordant monozygotic twins. Am J Psychiatry. 1992;149: 890–897.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
22. Korpi ER, Kleinman JE, Goodman SI, Philips I, DeLisi LE, Linnoila M, Wyatt RJ. Serotonin and 5-hydroxyindoleacetic acid in brains of suicide victims: comparison in chronic schizophrenic patients with suicide as cause of death. Arch Gen Psychiatry. 1986;43: 594–600.
23. Altshuler LL, Casanova MF, Goldberg TE, Kleinman JE. The hippocampus and parahippocampus in schizophrenic, suicide, and control brains. Arch Gen Psychiatry. 1990;47: 1029–1034.
24. Jones BN. Amino acid analysis by o-phthalaldehyde precolumn derivatization and reverse-phase HPLC. In: Shively JE, ed. Method of Protein Microcharacterization. Clifton, NJ: Humana Press; 1986: 121–151.
25. Koller K, Zaczek R, Coyle JT. N-acetyl-aspartyl glutamate: regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J Neurochem. 1984;43: 1136–1142.
26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem. 1951;193: 265–275.
27. Korpi ER, Kleinman JE, Goodman SI, Wyatt RJ. Neurotransmitter amino acids in post-mortem brains of chronic schizophrenic patients. Psychiatry Res. 1987;22: 291–301.
28. Tsai G, Slusher BS, Sim L, Hedreen JC, Rothstein JD, Kuncl R, Coyle JT. Reductions in acidic amino acids and N-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS. Brain Res. 1991;556: 151–156.
29. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience. 1991;45: 37–45.
30. Benes FM. Neurobiological investigations in cingulate cortex of schizophrenic brain. Schizophr Bull. 1993;19: 537–549.
31. Sekiguchi M, Okamoto K, Sakai Y. Excitatory action of N-acetyl-aspartylglutamate on Purkinje cells in guinea pig cerebellar slices: an intrasomatic study. Brain Res. 1987;423: 23–33.
32. Sekiguchi M, Okamoto K, Sakai Y. Low concentration N-acetyl-aspartylglutamate suppresses the climbing fiber response of Purkinje cells in guinea pig cerebellar slices and the responses to excitatory amino acids of Xenopus laevis oocytes injected with cerebellar mRNA. Brain Res. 1989;482: 87–96.
33. Thomson AM, Walker VE, Flynn DM. Glycine enhances NMDA-receptor mediated synaptic potentials in neocortical slices. Nature. 1989;338: 422–424.
34. Ishimaru M, Kurumaji A, Toru M. NMDA-associated glycine binding site increases in schizophrenic brains. Biol Psychiatry. 1992;32: 379–381.
35. Ishimaru M, Kurumaji A, Toru M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol Psychiatry. 1994;35: 84–95.
36. Kotter R. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog Neurobiol. 1994;44: 163–196.
37. Gattaz WF, Gattaz D, Beckmann H. Glutamate in schizophrenics and healthy controls. Arch Psychiatr Nervenkr. 1982;231: 221–225.
38. Procter AW, Wong EHF, Stratmann GC, Lowe SL, Bowen DM. Reduced glycine stimulation of [3H]MK-801 binding in Alzheimer's disease. J Neurochem. 1989;53: 698–704.
39. Mitchell IJ, Lawson S, Moser B, Laidlaw SM, Cooper AJ, Walkinshaw G, Waters CM. Glutamate-induced apoptosis results in a loss of striatal neurons in the parkinsonian rat. Neuroscience. 1994;63: 1–5.
40. Ulas J, Cotman CW. Excitatory amino acid receptors in schizophrenia. Schizophr Bull. 1993;19: 105–117.
41. Coyle JT, Ferkany JW, Zaczek R. Insights from a neurotoxin into the pathophysiology of Huntington's disease. Neurobehav Toxicol Teratol. 1983;5: 617–624.
42. Young AB, Greenamyre JT, Hollingsworth A. NMDA receptor losses in putamen from patients with Huntington's disease. Science. 1988;241: 981–983.
43. Roberts GW. Schizophrenia: a neuropathological perspective. Br J Psychiatry. 1991;158: 8–17.
44. McDonald JW, Johnston MV. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Rev. 1990;15: 41–70.
45. Coyle JT. Excitotoxins. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987: 333–340.
46. Deshpande JK, Tsai G, Stauch B, Passani L, Coyle JT. Ischemic changes of excitatory neurotransmitters in rat hippocampus. Soc Neurosci Abstr. 1990;16:1190. Abstract.